The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

SEPN is entitled to receive around $2.2 billion from NVO under the new collaboration deal, which aims to develop oral pills for obesity and other diseases.

Novo Nordisk NVO announced a significant partnership with Septerna SEPN, a U.S.-based biotech company, valued at up to $2.2 billion, to tap the growing obesity treatment market. F ...

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic ...

HealthDay News — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes, and other metabolic diseases.

Novo Nordisk and Septerna have entered a global collaboration to develop oral small molecule therapies for obesity, type 2 diabetes, and other cardiometabolic diseases, initially targeting four ...

Novo Nordisk CEO Lars Jørgensen to step down amid increasing pressure from obesity drug competition and recent share price ...

Novo Nordisk and Septerna will jointly carry out research on the candidates from discovery to development candidate selection, with the Danish pharma group taking over responsibility as they ...